The Department of Health and the ABPI have made a joint investment in the development of a common database for new medicines which will be used by NHS horizon scanning organisations to support better financial and service planning for the introduction of medicines into the NHS. The database is known as UK Pharmascan – www.ukpharmascan.org.uk.
Please note that access to UK Pharmascan is available only to registered pharmaceutical companies as well as NHS organisations which undertake horizon scanning activities for new medicines.
Benefits of UK Pharmascan
The benefits to pharmaceutical companies from using UK Pharmascan include:
A simple way to update just one source of data, which can then be viewed securely by all registered NHS horizon scanning organisations – including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Medicines Strategy Group (AWMSG), UK Medicines Information (UKMi) and the Medicines Prescribing Centre (MPC).
An eventual reduction of the need to make individual company submissions to multiple horizon scanning agencies, which can be duplicative and an inefficient use of resources.
A more productive and in-depth company dialogue with horizon scanning agencies about new medicines and indications.
Being recognised as a contributor to an innovative DH/NHS/ABPI/industry strategic partnership initiative to help improve and speed up access to new medicines within the NHS.
UK Pharmascan is hosted by NICE on behalf of DH and the NHS, and the operation and use of UK Pharmascan is managed by an independent Oversight and Governance Committee. For the benefits of UK Pharmascan to be fully realised for both the NHS and for industry, companies must enter details of all their pipeline medicines. To date, more than 120 pharmaceutical companies that share a common interest in improving and speeding up access to new medicines for patients in the NHS have registered to use UK Pharmascan.